Vera Therapeutics stock sinks following competitor’s successful trial

Investing.com -- Shares of Vera Therapeutics (NASDAQ: VERA) tumbled by 33% in premarket trading today after a Japanese competitor, Otsuka, reported positive results from a Phase 3 trial of a competing kidney disease therapy. Otsuka’s announcement indicated that its drug, sibeprenlimab, achieved a 51.2% reduction in proteinuria in the treatment of immunoglobulin A nephropathy (IgAN), surpassing the results from Vera’s own candidate, atacicept.

IgAN, a chronic kidney disease that often leads to end-stage kidney disease, typically affects adults between the ages of 20 and 40. The significant results from Otsuka’s sibeprenlimab come on the heels of the drug receiving Priority Review designation from the US Food and Drug Administration last month, signaling a potential accelerated approval process.

The news comes as a blow to Vera Therapeutics, whose recent data showed a 42% reduction in proteinuria with atacicept. While Vera’s results were previously hailed by analysts as a "home run," the latest developments from Otsuka have evidently shifted investor sentiment, casting doubt on Vera’s competitive position in the IgAN treatment market.

It is worth noting that the market’s reaction to Vera’s stock is a direct response to the comparative data released by Otsuka. Investors are likely weighing the potential impact on Vera’s market share and future revenue, given the promising results of Otsuka’s therapy.

You May Also Be Interested In

• Elliott targets Deutsche Telekom, opposes $300B T-Mobile merger - Bloomberg News
• Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
• Jefferies sees bottlenecks in critical minerals as electrification demand builds